Treatment with an estrogen receptor-beta-selective agonist is cardioprotective

Ivana Nikolic, Dianxin Liu, Jamie A. Bell, Jennifer Collins, Charles Jr Steenbergen, Elizabeth Murphy

Research output: Contribution to journalArticle

Abstract

This study was designed to investigate whether treatment with an estrogen receptor-beta (ER-β)-selective agonist (2,3-bis(4-hydroxyphenyl)-propionitrile, DPN) can provide cardioprotection in female mice lacking endogenous estrogen. To study the effect of ER-β stimulation in ischemia-reperfusion injury, we treated ovariectomized (ovx) female mice with 0.1 mg/kg/day of 17β-estradiol, 0.8 mg/kg/day of DPN, or vehicle for 2 weeks. Isolated hearts were Langendorff perfused for 25 min prior to a 1-min treatment with isoproterenol, followed by 20 min of normothermic global ischemia and 40 min of reperfusion. Left ventricular developed pressure (LVDP) and heart rate were measured. Recovery of function at the end of 40 min of reperfusion was expressed as a percentage of pre-ischemic rate pressure product (RPP = LVDP × heart rate). Hearts from ovx female mice had a significantly lower recovery of LVDP than the hearts from intact female mice (12.4 ± 1.6% vs. 19.6 ± 1.6%, p <0.05, respectively). Furthermore, hearts from ovx female mice treated with DPN exhibited significantly better functional recovery than hearts from either vehicle-treated ovx female mice (20.1 ± 2.2% vs. 12.4 ± 1.6%, p <0.05, respectively) or wild type male mice (20.1 ± 2.2% vs. 6.4 ± 0.6%, p <0.05, respectively). DPN did not increase uterine weight in ovx females compared to vehicle treatment. Gene profiling showed that treatment with DPN resulted in upregulation of a number of protective genes such as heat shock protein 70, the antiapoptotic protein, growth arrest and DNA damage 45 β, and cyclooxygenase 2.

Original languageEnglish (US)
Pages (from-to)769-780
Number of pages12
JournalJournal of Molecular and Cellular Cardiology
Volume42
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Estrogen Receptor beta
Ventricular Pressure
Reperfusion
Heart Rate
HSP70 Heat-Shock Proteins
Recovery of Function
Cyclooxygenase 2
Reperfusion Injury
Isoproterenol
Genes
DNA Damage
Estradiol
Estrogens
Up-Regulation
Ischemia
2,3-bis(4-hydroxyphenyl)-propionitrile
Pressure
Weights and Measures
Growth

Keywords

  • Cardioprotection
  • Estrogen
  • Heart
  • Ischemia

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. / Nikolic, Ivana; Liu, Dianxin; Bell, Jamie A.; Collins, Jennifer; Steenbergen, Charles Jr; Murphy, Elizabeth.

In: Journal of Molecular and Cellular Cardiology, Vol. 42, No. 4, 04.2007, p. 769-780.

Research output: Contribution to journalArticle

Nikolic, Ivana ; Liu, Dianxin ; Bell, Jamie A. ; Collins, Jennifer ; Steenbergen, Charles Jr ; Murphy, Elizabeth. / Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. In: Journal of Molecular and Cellular Cardiology. 2007 ; Vol. 42, No. 4. pp. 769-780.
@article{e192bc80fae142e2ad9cf0974633ce5a,
title = "Treatment with an estrogen receptor-beta-selective agonist is cardioprotective",
abstract = "This study was designed to investigate whether treatment with an estrogen receptor-beta (ER-β)-selective agonist (2,3-bis(4-hydroxyphenyl)-propionitrile, DPN) can provide cardioprotection in female mice lacking endogenous estrogen. To study the effect of ER-β stimulation in ischemia-reperfusion injury, we treated ovariectomized (ovx) female mice with 0.1 mg/kg/day of 17β-estradiol, 0.8 mg/kg/day of DPN, or vehicle for 2 weeks. Isolated hearts were Langendorff perfused for 25 min prior to a 1-min treatment with isoproterenol, followed by 20 min of normothermic global ischemia and 40 min of reperfusion. Left ventricular developed pressure (LVDP) and heart rate were measured. Recovery of function at the end of 40 min of reperfusion was expressed as a percentage of pre-ischemic rate pressure product (RPP = LVDP × heart rate). Hearts from ovx female mice had a significantly lower recovery of LVDP than the hearts from intact female mice (12.4 ± 1.6{\%} vs. 19.6 ± 1.6{\%}, p <0.05, respectively). Furthermore, hearts from ovx female mice treated with DPN exhibited significantly better functional recovery than hearts from either vehicle-treated ovx female mice (20.1 ± 2.2{\%} vs. 12.4 ± 1.6{\%}, p <0.05, respectively) or wild type male mice (20.1 ± 2.2{\%} vs. 6.4 ± 0.6{\%}, p <0.05, respectively). DPN did not increase uterine weight in ovx females compared to vehicle treatment. Gene profiling showed that treatment with DPN resulted in upregulation of a number of protective genes such as heat shock protein 70, the antiapoptotic protein, growth arrest and DNA damage 45 β, and cyclooxygenase 2.",
keywords = "Cardioprotection, Estrogen, Heart, Ischemia",
author = "Ivana Nikolic and Dianxin Liu and Bell, {Jamie A.} and Jennifer Collins and Steenbergen, {Charles Jr} and Elizabeth Murphy",
year = "2007",
month = "4",
doi = "10.1016/j.yjmcc.2007.01.014",
language = "English (US)",
volume = "42",
pages = "769--780",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment with an estrogen receptor-beta-selective agonist is cardioprotective

AU - Nikolic, Ivana

AU - Liu, Dianxin

AU - Bell, Jamie A.

AU - Collins, Jennifer

AU - Steenbergen, Charles Jr

AU - Murphy, Elizabeth

PY - 2007/4

Y1 - 2007/4

N2 - This study was designed to investigate whether treatment with an estrogen receptor-beta (ER-β)-selective agonist (2,3-bis(4-hydroxyphenyl)-propionitrile, DPN) can provide cardioprotection in female mice lacking endogenous estrogen. To study the effect of ER-β stimulation in ischemia-reperfusion injury, we treated ovariectomized (ovx) female mice with 0.1 mg/kg/day of 17β-estradiol, 0.8 mg/kg/day of DPN, or vehicle for 2 weeks. Isolated hearts were Langendorff perfused for 25 min prior to a 1-min treatment with isoproterenol, followed by 20 min of normothermic global ischemia and 40 min of reperfusion. Left ventricular developed pressure (LVDP) and heart rate were measured. Recovery of function at the end of 40 min of reperfusion was expressed as a percentage of pre-ischemic rate pressure product (RPP = LVDP × heart rate). Hearts from ovx female mice had a significantly lower recovery of LVDP than the hearts from intact female mice (12.4 ± 1.6% vs. 19.6 ± 1.6%, p <0.05, respectively). Furthermore, hearts from ovx female mice treated with DPN exhibited significantly better functional recovery than hearts from either vehicle-treated ovx female mice (20.1 ± 2.2% vs. 12.4 ± 1.6%, p <0.05, respectively) or wild type male mice (20.1 ± 2.2% vs. 6.4 ± 0.6%, p <0.05, respectively). DPN did not increase uterine weight in ovx females compared to vehicle treatment. Gene profiling showed that treatment with DPN resulted in upregulation of a number of protective genes such as heat shock protein 70, the antiapoptotic protein, growth arrest and DNA damage 45 β, and cyclooxygenase 2.

AB - This study was designed to investigate whether treatment with an estrogen receptor-beta (ER-β)-selective agonist (2,3-bis(4-hydroxyphenyl)-propionitrile, DPN) can provide cardioprotection in female mice lacking endogenous estrogen. To study the effect of ER-β stimulation in ischemia-reperfusion injury, we treated ovariectomized (ovx) female mice with 0.1 mg/kg/day of 17β-estradiol, 0.8 mg/kg/day of DPN, or vehicle for 2 weeks. Isolated hearts were Langendorff perfused for 25 min prior to a 1-min treatment with isoproterenol, followed by 20 min of normothermic global ischemia and 40 min of reperfusion. Left ventricular developed pressure (LVDP) and heart rate were measured. Recovery of function at the end of 40 min of reperfusion was expressed as a percentage of pre-ischemic rate pressure product (RPP = LVDP × heart rate). Hearts from ovx female mice had a significantly lower recovery of LVDP than the hearts from intact female mice (12.4 ± 1.6% vs. 19.6 ± 1.6%, p <0.05, respectively). Furthermore, hearts from ovx female mice treated with DPN exhibited significantly better functional recovery than hearts from either vehicle-treated ovx female mice (20.1 ± 2.2% vs. 12.4 ± 1.6%, p <0.05, respectively) or wild type male mice (20.1 ± 2.2% vs. 6.4 ± 0.6%, p <0.05, respectively). DPN did not increase uterine weight in ovx females compared to vehicle treatment. Gene profiling showed that treatment with DPN resulted in upregulation of a number of protective genes such as heat shock protein 70, the antiapoptotic protein, growth arrest and DNA damage 45 β, and cyclooxygenase 2.

KW - Cardioprotection

KW - Estrogen

KW - Heart

KW - Ischemia

UR - http://www.scopus.com/inward/record.url?scp=34047154988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047154988&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2007.01.014

DO - 10.1016/j.yjmcc.2007.01.014

M3 - Article

C2 - 17362982

AN - SCOPUS:34047154988

VL - 42

SP - 769

EP - 780

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 4

ER -